Navigation Links
Analysis of Earlier European Stroke Trial Supports Treatment Regimen for Viprinex(TM) in Current International Phase 3 Clinical Trials
Date:9/25/2008

HREF="http://studio-5.financialcontent.com/prnews?Page=Quote&Ticker=NTII" onClick="var s=s_gi(s_account); var hd1 = document.getElementById('headline'); s.tl(this,'o',getLinkName('Company Sanpshot'));" >NTII) is a biopharmaceutical company focused on developing novel, first-in-class agents for central nervous system conditions and other serious unmet medical needs. The Company's most advanced product candidate, Viprinex(TM) (ancrod), is in Phase 3 clinical testing as a novel investigational drug for the treatment of acute ischemic stroke. Viprinex has multiple mechanisms of action and is specifically designed to extend the time period that patients can be treated after the onset of a stroke. Acute ischemic stroke is one of the most prevalent, debilitating and costly diseases in the world for which there are few acceptable treatment options. NTI also has early-stage development programs for Alzheimer's and Huntington's diseases and rights to receive payments on an approved drug for Alzheimer's disease and an investigational drug in Phase 3 trials for brain swelling.

NOTE: Except for the historical information contained herein, the matters discussed in this press release are forward-looking statements that involve risks and uncertainties, including uncertainties regarding the development of Viprinex for acute ischemic stroke, delays or other problems with our clinical trials, the outcome of the interim analysis, the time and costs for obtaining approval for Viprinex, and levels of future expenditures and capital resources needed to fund operations, as well as other risks detailed from time to time in our filings with the Securities and Exchange Commission, including our Annual Report on Form 10-K, as updated periodically in Quarterly Reports on Form 10-Q and Current Reports on Form 8-K. Actual results may differ materially from those projected. These forward-looking statements represent our judgment as of the date of the release and we undertake no obligati
'/>"/>

SOURCE Neurobiological Technologies, Inc.
Copyright©2008 PR Newswire.
All rights reserved

Page: 1 2 3 4

Related medicine technology :

1. Trubion Announces Preliminary Analysis of Phase IIb Results With TRU-015 in Rheumatoid Arthritis
2. Oncology Drugs Development Update - Worldwide Markets and Forecasts of Approved EGFr/HEr2 Inhibitors, Treatment Costs, Pathway Analysis, Current and Expanded Clinical Indications, and Novel Agents in Development
3. New Data From Large Safety Analysis of MYCAMINE Shows Favorable Clinical Safety Profile
4. Immtech Announces Interim Analysis in Phase III African Sleeping Sickness Trial
5. Analysis Shows Vernakalant Hydrochloride Injection Increases Conversion to Normal Heart Rhythm in Acute Atrial Fibrillation Patients Treated Within 48 Hours of Onset
6. New Analysis of Study Data Shows That Asacol(R) (Mesalamine) Delivers Rapid Symptom Relief for Ulcerative Colitis Patients
7. A Sociolinguistic Analysis of In-Office Dialogue Reveals Psychiatrists and Parents Have Significantly Different Perceptions on ADHD and Psychiatric Comorbidities
8. Favrille Provides Update on Timing of Analysis from Pivotal Phase 3 Clinical Trial; Reports Third Quarter 2007 Financial Results
9. Results Of VYVANSE(TM) (lisdexamfetamine dimesylate) Effect Size Analysis Presented at Major Scientific Meeting
10. Progen Presents Additional Analysis of Data from PI-88 Phase 2 Liver Cancer Study at American Association for the Study of Liver Diseases
11. Retrospective Analysis Finds That Initiation of Insulin Glargine in Patients With Type 2 Diabetes was Associated With a Lower Incidence Rate of Myocardial Infarction as Compared With NPH Insulin
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:7/30/2015)...  Tandem Diabetes Care®, Inc. (NASDAQ: TNDM ... the t:slim® and t:flex™ Insulin Pumps, today announced ... with Dexcom, Inc. to allow the integration of ... G5 and G6 continuous glucose monitoring ("CGM") systems. ... with Dexcom,s future CGM systems is an important ...
(Date:7/30/2015)... VANCOUVER , July 30, 2015  OncoGenex Pharmaceuticals, ... will report its second quarter 2015 financial results on ... conference call and live webcast at 4:30 p.m. Eastern ... development programs and a general corporate update. ... Investor Relations page of the OncoGenex website at ...
(Date:7/30/2015)... July 30, 2015 Tianyin Pharmaceutical Inc. (NYSE ... that specializes in the patented biopharmaceutical, modernized traditional Chinese ... provided updates regarding the notice it received on May ... indicating that the Company was below certain of the ... 134 and 1101 of the NYSE MKT Company Guide, ...
Breaking Medicine Technology:Tandem Diabetes Care Announces Development Agreement with Dexcom for Integration of Future Generation CGM Systems 2Tandem Diabetes Care Announces Development Agreement with Dexcom for Integration of Future Generation CGM Systems 3TPI Provides Update Regarding Non-Compliance with NYSE MKT Continued Listing Requirements 2
... Given the narrow initial public offering window, declining venture ... become the exit of choice for many biopharmaceutical companies. In ... was higher, but it still wasn,t the flood of deals ... Another not-so-positive trend for biotech in 2011 was ...
... Independa™ announced today that it has closed ... that surpassed the target of $2.2 million indicating strong ... solutions that enhance independence for older adults. ... top of $1.6 million in seed-round venture capital funding ...
Cached Medicine Technology:Biopharma M&A Trends Hold Steady, But Deals Declined in 2011 2Independa Closes Convertible Note Funding at $2.35 Million 2Independa Closes Convertible Note Funding at $2.35 Million 3
(Date:8/1/2015)... (PRWEB) , ... August 02, 2015 , ... AlignLife ... which will help the continuity of care for patients at this natural health care ... the unknown," Clinic Director Mary Heal said. "Heather's role is vital to our approach ...
(Date:8/1/2015)... ... 2015 , ... Calvary Hospital today announced that it is embarking on a ... is to bring this Torah – dating from 1880 – back to kosher status, ... , Scroll No. 515, from the town of Taus-Domazlice, is on permanent loan ...
(Date:8/1/2015)... Atlanta, GA (PRWEB) , ... August 01, 2015 , ... ... iPhone app that is free to download on the Apple AppStore. , The ... energy levels, even mood, thus acting as a tool to view personal health and ...
(Date:7/31/2015)... ... ... a reputable source of authentic tickets for the 2015 iHeart Radio Music Festival ... music will have an act they are excited to see at this two-day festival. ... perform: Sam Smith, Coldplay, Kenny Chesney, The Who, Jason Derulo, Demi Lovato, Duran Duran, ...
(Date:7/31/2015)... ... ... Precision Aesthetics is New York’s only Thermage skin tightening pinnacle and black diamond award ... fat reduction in New York. Due to its unparalleled level of experience for ... patients travel to New York to get their non-surgical skin tightening and body shaping ...
Breaking Medicine News(10 mins):Health News:New Patient Advocate Enhances Natural Health Care 2Health News:Calvary Hospital Announces Plans to Restore Historic Torah 2Health News:Calvary Hospital Announces Plans to Restore Historic Torah 3Health News:Lume Wellness Launches Health and Fitness Tracker iPhone App 2Health News:Cheap 2015 iHeartRadio Music Festival Tickets in Las Vegas at MGM Grand Garden Arena: Ticket Down Slashes Ticket Prices on the iHeart Radio Music Festival in Vegas 2Health News:Cheap 2015 iHeartRadio Music Festival Tickets in Las Vegas at MGM Grand Garden Arena: Ticket Down Slashes Ticket Prices on the iHeart Radio Music Festival in Vegas 3
... , , NEW YORK, Sept. 1 Empire ... status of "Excellent" for its HMO Commercial HMO/POS Combined and Medicare ... accreditation status - the highest possible level - is based on ... members receive access to high quality care. , , ...
... aggressive tumors if pounds mount up in 20s, 30s, study ... pack on excess pounds as young adults are at heightened ... ethnic group, researchers from the University of Hawaii report. , ... colorectal cancer and breast cancer in postmenopausal women. However, whether ...
... and Washington DC (1 September 2009) SAGE, the ... to announce a new agreement with the International Headache ... . Now in its 29th volume, Cephalalgia ... review articles and short communications on all aspects of ...
... 1, 2009 A recent study published in the ... correlation between being overweight, smoking and breast cancer. What ... not diagnosed for BRCA1 and BRCA2 gene mutations, which ... with such gene mutations were excluded to allow researchers ...
... , , Program Helps Teachers ... , WASHINGTON, Sept. 1 With worries about the ... Education Association Health Information Network (NEA HIN) and The Clorox Company are ... 2 through September 5, 2009, teachers nationwide can visit www.CloroxClassrooms.com ...
... , HARRISBURG, Pa., Sept. 1 ... interested in receiving pandemic H1N1 influenza vaccines and supplies when ... today. , , The Department of ... schools and community vaccinators. , , ...
Cached Medicine News:Health News:Empire Blue Cross Blue Shield Awarded NCQA's Accreditation Status of 'Excellent' 2Health News:Adult Weight Gain Tied to Prostate Cancer Risk 2Health News:SAGE to publish leading international headache journal Cephalalgia 2Health News:Breast cancer: Risk increases for smokers and overweight women 2Health News:National Education Association Health Information Network (NEA HIN) and The Clorox Company Offer Free Disinfecting Wipes to Teachers Nationwide 2Health News:National Education Association Health Information Network (NEA HIN) and The Clorox Company Offer Free Disinfecting Wipes to Teachers Nationwide 3Health News:Pennsylvania Department of Health Launches Online H1N1 Vaccine Registry 2
... ARUP Laboratories is a national reference ... laboratory research and development. ARUP offers an ... unique medical tests in clinical and anatomic ... ARUP Laboratories' clients include more than half ...
... reference laboratory and a worldwide leader in ... an extensive test menu of highly complex ... anatomic pathology. Owned by the University of ... half of the nation's university teaching hospitals ...
... reference laboratory and a worldwide leader in ... an extensive test menu of highly complex ... anatomic pathology. Owned by the University of ... half of the nation's university teaching hospitals ...
... is a national reference laboratory and a ... development. ARUP offers an extensive test menu ... in clinical and anatomic pathology. Owned by ... include more than half of the nation's ...
Medicine Products: